Edwards Lifesciences Corporation (EW) Stock
NYSEEW has an Alpha Score of 46 out of 100 (weak), computed on Nov 12, 2026 from 3 of 4 sub-scores. 16 members of Congress disclosed 30 trades in EW since 2014: 14 purchases and 16 sales, most recently Alan Armstrong (purchase, Mar 27, 2026). 6 of the hedge funds AlphaScala tracks reported EW in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $361.65M. Company insiders reported 0 open-market buys and 11 sales on SEC Form 4 in the 90 days to Nov 13, 2026. Its trailing P/E ratio is 57.8 and its net margin 15.3% (key statistics as of Nov 11, 2026).
What is EW's Alpha Score?
How it works →Alpha Score of 46 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 12, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Edwards Lifesciences Corporation (EW)?
Most recent: Alan Armstrong (purchase, Mar 27, 2026); records start Feb 14, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-11-19 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $50k – $100k |
| Bruce Westerman R-AR · House | 2025-04-21 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-04-07 | purchase | $15k – $50k |
| Bruce Westerman R-AR · House | 2025-03-03 | purchase | $1k – $15k |
| Markwayne Mullin R-OK · Senate | 2024-08-20 | partial sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 13, 2026. Senate records here end Nov 4, 2026; later Senate trades are not included.
See all EW political trades →Which hedge funds own EW?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 4.00M | $361.65M | +670% |
| Millennium Management Israel Englander | 3.58M | $324.28M | +100% |
| Point72 Steve Cohen | 1.77M | $160.49M | -3% |
| Bridgewater Associates Ray Dalio | 275K | $24.90M | +60% |
| Renaissance Technologies Jim Simons (founder) | 105K | $9.05M | +400% |
| Marshall Wace | 80K | $6.91M | -77% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Edwards Lifesciences Corporation insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 10, 26 | Lippis Daniel J. | CVP, TAVR | SELL | 619 | $65K |
| Nov 9, 26 | Bobo Donald E Jr | CVP,Strategy/Corp Development | SELL | 48.9K | $5.0M |
| Nov 9, 26 | Zovighian Bernard J | CEO | SELL | 9.2K | $949K |
| Nov 9, 26 | Zovighian Bernard J | CEO | SELL | 13.9K | $1.4M |
| Oct 8, 26 | Lippis Daniel J. | CVP, TAVR | SELL | 619 | $53K |
| Sep 11, 26 | Lippis Daniel J. | CVP, TAVR | SELL | 619 | $54K |
| Aug 31, 26 | Dahl Andrew M. | SVP, Corporate Controller | SELL | 544 | $50K |
| Aug 28, 26 | Bruls Annette | CVP, EMEACLA | SELL | 2.6K | $238K |
| Aug 26, 26 | Markowitz Wayne | CVP, JAPAC | SELL | 1.2K | $113K |
| Aug 26, 26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | SELL | 1.2K | $106K |
SEC Form 4 filings as of Nov 13, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →What are EW's key statistics?
Key statistics as of Nov 11, 2026
How does EW's valuation compare with the Healthcare sector?
| Metric | EW | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 57.8 | 27.3 | 136 |
| Net margin | 15.30% | 3.60% | 205 |
| Return on equity | 9.69% | 4.11% | 232 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 17, 2026). P/E excludes loss-making companies.
EW price chart
Powered by TradingViewWhat does Edwards Lifesciences Corporation do?
Edwards Lifesciences Corporation is the leading global structural heart innovation company, specializing in patient-focused medical devices for structural heart disease, critical care, and surgical monitoring. The company develops and commercializes breakthrough technologies, including pioneering transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions, to address unmet needs in cardiovascular care through minimally invasive procedures. Its product portfolio encompasses heart valve therapies and monitoring systems that enhance patient outcomes and quality of life. Edwards Lifesciences Corporation collaborates with leading clinicians and researchers worldwide to deliver innovations in structural heart procedures, such as TAVR and mitral platforms, alongside critical care technologies. These offerings serve healthcare providers globally, emphasizing structural heart disease management and procedural efficiency. Founded in 2000 and headquartered in Irvine, California, Edwards Lifesciences Corporation plays a pivotal role in the medical device industry by advancing cardiovascular solutions and supporting clinical advancements in heart care.